A biotech, short for biotechnology company, is a business that uses living organisms, cells, or biological processes to develop products. These products span medicine, agriculture, energy, and manufacturing. The global biotech market was valued at roughly $1.55 trillion in 2023 and is projected to nearly double by 2030, growing at about 14% per year.
The term “biotechnology” itself covers a massive range of work. At its simplest, it means using biology to solve problems or make useful things. Humans have been doing this for thousands of years through brewing beer, making cheese, and selectively breeding crops. Modern biotech takes it further by working directly with DNA, proteins, and cellular machinery to create therapies, engineered crops, biofuels, and more.
How Biotech Differs From Pharma
People often use “biotech” and “pharma” interchangeably, but the two industries work in fundamentally different ways. Traditional pharmaceutical companies create drugs through chemical synthesis, producing small molecules in a lab. Think of a common painkiller or cholesterol medication: those are typically chemicals built from scratch.
Biotech companies, by contrast, use living cells or organisms to produce their products. The resulting drugs, called biologics, are large, complex molecules like proteins, hormones, or antibodies derived from living systems. A classic example: human insulin is now produced by genetically modified bacteria grown in massive fermentation tanks. Vaccines, gene therapies, and diagnostic tools also fall under the biotech umbrella. Some companies straddle both worlds, and the industry sometimes uses “biopharma” as a catch-all term.
Medical Biotech
Medicine is the highest-profile branch of biotechnology. Companies in this space develop treatments that work at the genetic or cellular level, including therapeutic proteins, mRNA vaccines (the technology behind certain COVID-19 shots), and gene therapies designed to correct faulty DNA.
The biggest biotech companies by market value are household names in healthcare. AbbVie, Gilead Sciences, and Amgen rank among the largest, alongside Vertex Pharmaceuticals, which focuses on treatments for genetic diseases like cystic fibrosis. Illumina, another major player, builds the machines that sequence DNA, providing the foundation for much of modern genomic medicine.
Agricultural Biotech
Biotech in agriculture centers on genetically engineered crops. The first commercially sold transgenic crop was the “Flavr Savr” tomato in the 1990s, engineered so a ripening enzyme was dialed down, giving the fruit a longer shelf life. Since then, the field has expanded dramatically. Insect-resistant corn and cotton that produce their own pest-killing protein, along with herbicide-tolerant soybeans, became some of the most widely adopted agricultural technologies in American farming.
Newer crop engineering aims beyond pest resistance. Researchers are working on grains with higher nutritional value, fruits and vegetables with longer shelf life, and seeds with increased vitamins and micronutrients. Some projects focus on removing allergens or antinutritional compounds from food crops. Engineers have also inserted pest-resistance genes into trees, protecting hybrid poplars from leaf beetle damage, which is useful for establishing and maintaining young forests.
There’s also an environmental angle. Plants have been engineered to absorb pollutants from contaminated soil, a process called phytoremediation. Some plants can now accumulate mercury at more than 1% of their total dry weight, offering a potential way to clean up toxic sites by essentially growing the contamination out of the ground, then harvesting and safely disposing of the plants.
Industrial Biotech
Industrial biotechnology uses living cells (yeast, bacteria, molds) and their enzymes to manufacture products that are easier to break down, require less energy to produce, and generate less waste. You’ve likely encountered this branch without realizing it. Bacterial enzymes have been used in food manufacturing for decades, and they’re a key active ingredient in laundry detergents, where they break down fats and protein-based stains. The first rationally designed enzyme for this purpose hit the market in 1988.
One major goal has been biodegradable plastics. Certain bacteria naturally produce a type of polyester as an energy reserve. One species can accumulate up to 85% of its dry weight as this bioplastic material, essentially turning the microorganism into a tiny plastic factory. Researchers have even transferred the relevant genes into plants, opening a path toward growing plastic precursors in fields rather than refining them from petroleum.
Biofuels are another pillar. Starch from corn, potatoes, sugar cane, and wheat already feeds ethanol production as a gasoline substitute. Henry Ford’s first car actually ran on ethanol. Current research focuses on developing better bacterial enzymes that can break down agricultural waste (stalks, husks, wood chips) into simple sugars, creating a cheaper and more abundant raw material for fuel production.
Gene Editing and CRISPR
The technology that has most transformed biotech in the past decade is CRISPR, a gene-editing tool often described as “genetic scissors.” It works in three steps. First, a small piece of guide RNA is designed to match a specific stretch of DNA in a target gene. Second, a protein called Cas-9 latches onto that spot and cuts both strands of the DNA. Third, the cell’s own repair machinery fixes the break, either disabling the gene or inserting a corrected version.
The precision of this system has opened doors across medicine. CRISPR-based therapies are being investigated for sickle cell disease, cystic fibrosis, Duchenne muscular dystrophy, certain cancers, and HIV. Beyond medicine, the technology is being applied to crop improvement, livestock breeding, and basic biological research.
Ethical Questions in Biotech
The power to edit genes raises serious ethical concerns, particularly around germline editing, which means changes to eggs, sperm, or embryos that would be inherited by future generations. As of 2014, roughly 40 countries had discouraged or banned germline editing research, including 15 nations in Western Europe. Most bioethicists agree that germline editing for reproductive purposes should not be attempted until it is proven safe, citing two key risks: off-target effects (edits landing in the wrong spot) and mosaicism (where only some cells carry the intended change).
Consent is another thorny issue. When you edit an embryo, the person most affected by that edit, the future child, cannot consent to it. And if those changes pass to their children, the circle of people who never consented grows with each generation. There are also equity concerns. If powerful genetic therapies remain expensive, they could widen existing gaps in healthcare access. Some ethicists worry that unchecked enhancement, editing genes not to treat disease but to boost traits like intelligence or athleticism, could eventually create genetic class divisions.
How Biotech Products Reach the Market
In the United States, biotech products derived from living organisms go through a distinct regulatory path. Rather than the standard drug application used for chemically synthesized medications, biologics require a Biologics License Application filed with the FDA. This submission includes applicant and manufacturing information, preclinical study data, clinical trial results, and proposed labeling. The process ensures that products made from living systems, which are inherently more complex and variable than chemical drugs, meet safety and efficacy standards before reaching patients.
This regulatory complexity is one reason biotech products tend to be expensive and slow to develop. A single biologic therapy can take over a decade from initial research to market approval, with clinical trials costing hundreds of millions of dollars. It’s also why the biotech industry is heavily driven by venture capital and public investment: the upfront costs are enormous, but the potential payoff for a successful therapy can be transformative, both medically and financially.